Schizophrenia and increased risks of cardiovascular disease

2005/12/01 by Charles H. Hennekens, Alissa R. Hennekens, Danielle Hollar +1 · 31 citations
Medicine · Psychology · Neuroscience · #Schizophrenia research and treatment #Healthcare Decision-Making and Restraints #Tryptophan and brain disorders

paper · doi:10.1016/j.ahj.2005.02.007

Cited by

• Centrality statistics of symptom networks of schizophrenia: a systematic review
• Unhealthy lifestyle in early psychoses: The role of life stress and the hypothalamic–pituitary–adrenal axis
• Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
• Evaluation of autonomic nervous system by salivary alpha-amylase level and heart rate variability in patients with schizophrenia
• What is behind the 17-year life expectancy gap between individuals with schizophrenia and the general population?
• Individual Dietetic Consultations in First Episode Psychosis: A Novel Intervention to Reduce Cardiometabolic Risk
• The evolution of drug development in schizophrenia: past issues and future opportunities. [europepmc]
• Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. [europepmc]
• Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. [europepmc]
• Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. [europepmc]
• Cigarette smoking and mortality risk in people with schizophrenia. [europepmc]
• Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. [europepmc]
• Testing the hypothesis of accelerated cerebral white matter aging in schizophrenia and major depression. [europepmc]
• Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. [europepmc]
• Microvascular abnormality in schizophrenia as shown by retinal imaging. [europepmc]
• The genomics of schizophrenia: update and implications. [europepmc]
• Comorbidity profile and healthcare utilization in elderly patients with serious mental illnesses. [europepmc]
• Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. [europepmc]
• Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction. [europepmc]
• Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. [europepmc]
• Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables. [europepmc]
• Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. [europepmc]
• Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia? [europepmc]
• A widening longevity gap between people with schizophrenia and general population: A literature review and call for action. [europepmc]
• Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder. [europepmc]
• Stress, Telomeres, and Psychopathology: Toward a Deeper Understanding of a Triad of Early Aging. [europepmc]
• Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects. [europepmc]
• Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. [europepmc]
• Statins and Inflammation: New Therapeutic Opportunities in Psychiatry. [europepmc]
• Schizophrenia and Epigenetic Aging Biomarkers: Increased Mortality, Reduced Cancer Risk, and Unique Clozapine Effects. [europepmc]
• Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. [europepmc]